Creabilis
Samone · Founded 2003
About Creabilis
Creabilis is an emerging European specialty pharmaceutical company focused on dermatology. Creabilis discovers, develops and commercialises new medicines for a range of skin disorders, - an area of significant unmet medical need and high commercial potential. Creabilis has an exceptional track record in dermatological research and has used this experience to generate a rich pipeline of clinical and pre-clinical drug candidates that the company will market directly or in partnership. The most advanced product is CT327 for the treatment of psoriasis. CT327 will enter Phase II clinical trials in 2009. Creabilis' pipeline also includes a number of pre-clinical drug candidates arising from its ground breaking drug discovery programmes.
Company Facts
- Founded: 2003
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $51.4M
- Funding stage: M&A
- Last round: Series B (Oct 2011)
- Website: creabilis-sa.com
- Phone: +352 026-420-522
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/creabilis-3002914 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.